Journal Mobile Options
Table of Contents
Vol. 48, No. 1, 2003
Issue release date: July 2003
Neuropsychobiology 2003;48:35–40
(DOI:10.1159/000071827)

The Combined Effects of Apolipoprotein E Polymorphism and Low-Density Lipoprotein Cholesterol on Cognitive Performance in Young Adults

Puttonen S. · Elovainio M. · Kivimäki M. · Lehtimäki T. · Keltikangas-Järvinen L.
aDepartment of Psychology, University of Helsinki, Helsinki, bLaboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Centre for Laboratory Medicine, University Hospital of Tampere, and Tampere University Medical School, Department of Clinical Chemistry, Tampere, Finland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

This study examined the relations of apolipoprotein E (ApoE) genotype and the low-density lipoprotein (LDL) cholesterol level to cognitive performance of 57 randomly selected healthy young adults. From the ongoing population-based study of Cardiovascular Risk in Young Finns, 25 men and 32 women were ApoE genotyped and participated in mental arithmetic and reaction time tasks. In contrast to findings obtained from studies with elderly subjects, ApoE4 polymorphism was associated with better cognitive performance. In addition, LDL cholesterol moderated this association. In the ApoE4 genotype group, low LDL cholesterol was associated with good performance in the mental arithmetic test, whereas for those without ApoE4 genotype, low LDL cholesterol was associated with poor performance. Performance in the reaction time task did not differ between the ApoE groups. In conclusion, assessment of the influence of ApoE on cognitive performance may require taking additional physiological factors, such as the level of cholesterol, into account.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mortimer BC, Redgrave TG, Spangler EA, Verstuyft JG, Rubin EM: Effect of human apoE4 on the clearance of chylomicron-like lipid emulsions and atherogenesis in transgenic mice. Arterioscler Thromb 1994;14:1542–1552.
  2. Mahley RW, Rall SC Jr: Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507–537.
  3. Ravaja N, Räikkonen K, Lyytinen H, Lehtimäki T, Keltikangas-Järvinen L: Apolipoprotein E phenotypes and cardiovascular responses to experimentally induced mental stress in adolescent boys. J Behav Med 1997;20:571–587.
  4. Stengård JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF: Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265–269.
  5. Staehelin HB, Perrig-Chiello P, Mitrache C, Miserez AR, Perrig WJ: Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol Scand 1999;100:53–60.
  6. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ: The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. J Am Geriatr Soc 2001;49:1148–1155.
  7. Helkala EL, Koivisto K, Hänninen T, Vanhanen M, Kervinen K, Kuusisto J, Mykkänen L, Kesäniemi YA, Laakso M, Riekkinen P Sr: The association of apolipoprotein E polymorphism with memory: A population-based study. Neurosci Lett 1995;19:141–144.
  8. Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ: Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer’s disease. Psychol Aging 1999;14:295–303.
  9. Parasuraman R, Greenwood PM, Sunderland T: The apolipoprotein E gene, attention, and brain function. Neuropsychology 2002;16:254–274.
  10. Mayeux R, Small SA, Tang M, Tycko B, Stern Y: Memory performance in healthy elderly without Alzheimer’s disease: Effects of time and apolipoprotein-E. Neurobiol Aging 2001;22:683–689.

    External Resources

  11. Plassman BL, Welsh-Bohmer KA, Bigler ED, Johnson SC, Anderson CV, Helms MJ, Saunders AM, Breitner JC: Apolipoprotein E epsilon4 allele and hippocampal volume in twins with normal cognition. Neurology 1997;48:985–989.
  12. Small GW, Chen ST, Komo S, Ercoli L, Bookheimer S, Miller K, Lavretsky H, Saxena S, Kaplan A, Dorsey D, Scott WK, Saunders AM, Haines JL, Roses AD, Pericak-Vance MA: Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am J Psychiatry 1999;156:1035–1038.
  13. Smith GE, Bohac DL, Waring SC, Kokmen E, Tangalos EG, Ivnik RJ, Petersen RC: Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer’s disease but not in healthy control subjects. Neurology 1998;50:355–362.
  14. Small BJ, Graves AB, McEvoy CL, Crawford FC, Mullan M, Mortimer JA: Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology 2000;54:2082–2088.
  15. Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL, Currie J: Memory decline in healthy older people: Implications for identifying mild cognitive impairment. Neurology 2001;56:1533–1538.
  16. Hubacek JA, Pitha J, Skodova Z, Adamkova V, Lanska V, Poledne R: A possible role of apolipoprotein E polymorphism in predisposition to higher education. Neuropsychobiology 2001;43:200–203.
  17. Barres BA, Smith S J: Cholesterol – Making or breaking the synapse. Science 2002;294:1296–1297.

    External Resources

  18. Horsten M, Wamala SP, Vingerhoets A, Orth-Gomer K: Depressive symptoms, social support, and lipid profile in healthy middle-aged women. Psychosom Med 1997;59:521–528.
  19. Freedman DS, Byers T, Barrett DH, Stroup NE, Eaker E, Monroe-Blum H: Plasma lipid levels and psychological characteristics in men. Am J Epidemiol 1995;141:507–517.
  20. Terao T, Iwata N, Kanazawa K, Takano T, Takahashi N, Hayashi T, Sugawara Y: Low serum cholesterol levels and depressive state in human dock visitors. Acta Psychiatr Scand 2000;101:231–234.
  21. Strandberg TE, Räikkonen K, Partinen M, Pihl S, Vanhanen H, Miettinen TA, Associations of cholesterol lowering by statins with anger and hostility in hypercholesterolemic men. Biol Psychiatry 1994;35:575–577.
  22. Coutu MF, Dupuis G, D’Antono B: The impact of cholesterol lowering on patients’ mood. J Behav Med 2001;24:517–536.
  23. Muldoon MF, Ryan CM, Matthews KA, Manuck SB: Serum cholesterol and intellectual performance. Psychosom Med 1997;59:382–387.
  24. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population-based study. BMJ 2001;322:1447–1451.
  25. Ordovas JM, Schaefer EJ: Genes, variation of cholesterol and fat intake and serun lipids. Curr Opin Lipidol 1999;10:15–22.
  26. Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D: How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry 2001;158:848–856.
  27. Åkerblom H K, Uhari M, Pesonen E, Dahl M, Kaprio EA, Nuutinen EM, Pietikäinen M, Salo MK, Aromaa A, Kannas L, Keltikangas-Järvinen L, Kuusela V, Räsänen L, Rönnemaa T, Knip M, Telama R, Välimäki I, Pyörälä K, Viikari J: Cardiovascular risk in young Finns. Ann Med 1991;23:35–40.
  28. Keltikangas-Järvinen L, Räikkönen K, Lehtimäki T: Dependence between apolipoprotein E phenotypes and temperament in children, adolescents, and young adults. Psychosom Med 1993;55:155–156.
  29. Cacioppo J, Malarkey W, Kiecolt-Glacer J, Uchino B, Sgoutas-Emch S, Sheridan J, Berntson G, Glaser R: Heterogeneity in neuroendocrine and immune responses to brief psychological stressors as a function of autonomic cardiac activation. Psychosom Med 1995;57:154–164.
  30. Cohen J, Cohen P: Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences, ed 2. Hillsdale, Erlbaum, 1983.
  31. Deloche G, Hannequin D, Carlomagno S, Agniel A, Dordain M, Pasquier F, Pellat J, Denis P, Desi M, Beauchamp D: Calculation and number processing in mild Alzheimer’s disease. J Clin Exp Neuropsychol 1995;17:634–639.
  32. Rosselli M, Ardila A, Arvizu L, Kretzmer T, Standish V, Liebermann J: Arithmetical abilities in Alzheimer disease. Int J Neurosci 1998;96:141–148.
  33. Wechsler D: Wechsler Memory Scale – Revised. New York, Psychological Corporation, 1986.
  34. Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 2001;56:1683–1689.
  35. Helbecque N, Berr C, Cottel D, Fromentin-David I, Sazdovitch V, Ricolfi F, Ducimetière P, Di Menza C, Amouyel P: VLDL receptor polymorphism, cognitive impairment, and dementia. Neurology 2001;56:1183–1188.
  36. Smith U: Life style and genes-the key factors for diabetes and the metabolic syndrome. J Intern Med 1992;232:99–101.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50